glp-1 drug tirzepatide The Best on the Market Is Even Better Than We Knew Tirzepatide Associated with Lower POAG,

Description

For all their promise, GLP-1 and dual GIP/GLP-1 receptor agonists have raised more questions, particularly regarding their long-term safety implications

Conclusions In this real-word study, GLP-1RA was associated with a lower risk of AF compared with DPP4i, but no difference compared with SGLT2i, suggesting that cardiovascular benefits of GLP-1RA use may extend to prevention for AF in patients with diabetes

GLP-1 RA Recommendations In studies evaluating combined GLP-1 RA with nutrition and lifestyle interventions, individuals receiving both GLP-1 RAs and structured dietary guidance achieved greater weight loss, better adherence, and were more likely to sustain weight loss after discontinuing GLP-1 RAs compared to those receiving the medication alone 27

These benefits occur through blood pressure reduction (1-5.4 mmHg lower systolic blood pressure) 10 , improved vascular function, and direct effects on the heart

The primary cardiovascular end-point event occurred in 569 of the 8803 patients (6.5%) in the semaglutide group and 701 of the 8801 patients (8.0%) in the placebo group (Lincoff et al